Triple-Drug cocktail aims to extend remission in ovarian cancer
NCT ID NCT04742075
First seen Feb 28, 2026 · Last updated May 08, 2026 · Updated 13 times
Summary
This study tests whether a combination of three drugs (olaparib, durvalumab, and UV1) can help keep ovarian cancer from coming back in people whose tumors do not have a BRCA gene mutation. About 188 participants with recurrent ovarian cancer will receive this combination as maintenance therapy after standard platinum chemotherapy. The goal is to see if the combination improves the time before the cancer progresses compared to standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rigshospitalet
København Ø, Region Sjælland, 2100, Denmark
Conditions
Explore the condition pages connected to this study.